

1 Declining Trend of Sudden Cardiac Death in Younger 2 Individuals: A 20–Year Nationwide Study

3

4 Running title: 20-year Temporal Trends in Young SCD

5 Authors

6 Carl Johann Hansen MD^{a,b}, Jesper Svane MD PhD^{a,b}, Peder Emil Warming MD^a, Thomas
7 Hadberg Lyngø MD PhD^a, Rodrigue Garcia MD PhD^{a,c,d}, Carolina Malta Hansen MD PhD^e,
8 ^{f,g}, Christian Torp-Pedersen MD DMSc^{h,i}, Jytte Banner MD PhD^b, Bo Gregers Winkel MD
9 PhD^{a,*}, Jacob Tfelt-Hansen MD DMSc^{a,b,*}

10 *Authors contributed equally

11 Affiliations

12 ^aDepartment of Cardiology, Copenhagen University Hospital - Rigshospitalet,
13 Blegdamsvej 9, 2100 Copenhagen, Denmark

14 ^bDepartment of Forensic Medicine, Frederik Vs Vej 11, 2100 Copenhagen University,
15 Denmark

16 ^cUniversity Hospital of Poitiers. Cardiology Department, 2 rue de la Milétrie, 86021
17 Poitiers, France

18 ^dCentre d'Investigation Clinique 1402. CHU de Poitiers, 2 rue de la Milétrie, 86021
19 Poitiers, France

20 ^eCopenhagen Emergency Medical Services, Telegrafvej 5, 2750 Ballerup, Denmark

21 ^fHerlev and Gentofte Hospital, Department of Cardiology, Gentofte Hospitalsvej 1, 2900
22 Hellerup, Denmark

23 ^gDepartment of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2100
24 Copenhagen, Denmark

25 ^hDepartment of Cardiology, Nordsjællands Hospital, Dyrehavevej 29, 3400 Hillerød,
26 Denmark

27 ⁱDepartment of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1353
28 Copenhagen, Denmark

29

30 Corresponding author:

31 Carl Johann Hansen, MD. Department of Cardiology, Copenhagen University Hospital –
32 Rigshospitalet, 2142, Blegdamsvej 9, 2100 Copenhagen, Denmark.

33 Tel: (+45) 61 71 53 00. Email: carl.johann.hansen@regionh.dk

34 Word count: 7452

35 Abstract

36 Background

37 Declining all-cause and cardiovascular mortality rates have been well-documented, yet
38 temporal trends of sudden cardiac death (SCD) in the young are unclear. We provide
39 contemporary nationwide estimates of the incidence and temporal trends of SCD in the
40 young aged 1–35 from 2000–2019 and evaluate these trends in relation to changes in
41 out-of-hospital cardiac arrest (OHCA) patterns and implantable cardioverter
42 defibrillator (ICD) implantations.

43 Method

44 All individuals aged 1–35 living in Denmark from 2000–2019 were included.
45 Adjudication of SCD cases relied on multiple sources, including death certificates,
46 medical files, and autopsy reports. All OHCA were captured in a nationwide prospective
47 registry, and ICD implantations were registered through administrative registries. Crude
48 and sex- and age-standardized annual incidence rates of SCD were calculated, and
49 temporal changes in SCD incidence were computed as percentage change annualized
50 (PCA). Trends in OHCA survival and characteristics, as well as ICD implantations, were
51 assessed.

52 Results

53 During the 20-year study period (47.5 million person-years), 1 057 SCD were identified
54 (median age 29 years, 69% male sex). The overall incidence of SCD was 2.2 per 100 000

55 person-years and declined by 3.31% (95%CI 2.42 to 4.20) annually, corresponding to a
56 49.0% (95%CI 38.7 to 57.6) reduction during the study. Rates of witnessed SCD declined
57 markedly (PCA -7.03% [95%CI -8.57 to -5.48]), but we observed no changes in the rate
58 of unwitnessed SCD (PCA -0.09% [95%CI -1.48 to 1.31]). Consequently, the proportion
59 of unwitnessed SCD increased by 79% ($p < 0.001$). Survival after OHCA in young
60 individuals aged 1–35 increased from 3.9% to 28% in the same time frame, mainly
61 attributable to increased bystander CPR and defibrillation. The implantation rate of ICD
62 increased from 0.76 to 1.55 per 100 000 PY, and the prevalence of young individuals
63 with an ICD increased 16-fold.

64 Conclusion

65 SCD incidence rates in the young declined by 49% over the last two decades. The
66 decline was paralleled by improved survival in OHCA victims and higher ICD
67 implantation rates. However, rates of unwitnessed SCD were unchanged, which calls for
68 new perspectives in preventive strategies.

69 Keywords

70 Sudden cardiac death, epidemiology, temporal trends, prevention, resuscitation,
71 cardiac arrest

72

73

74 Clinical Perspectives

75 What is new? (max 100 words, 2-3 bullets)

- 76
- Over the past 20 years, the incidence of SCD in young individuals aged 1–35
- 77 declined by 49%.
- 78
- Concomitantly, the 30-day survival after OHCA increased from 4% to 28%,
- 79 driven by improved bystander CPR rates reaching +80%, and ICD implantations
- 80 in young adults increased markedly.
- 81
- We observed no decline in the incidence of unwitnessed SCD during the study
- 82 period.

83 What are the clinical implications (max 100 words, 2-3 bullets)

- 84
- As the majority (73%) of SCD in the most recent years were unwitnessed,
- 85 preventive strategies targeting unwitnessed cardiac arrests need further
- 86 attention. Incorporating connected devices, e.g. smart watches, in prevention
- 87 could potentially help identify ventricular arrhythmias and thus improve
- 88 survival among unwitnessed cardiac arrest.
- 89
- Low bystander AED rates (8%) call for further improvement in early AED
- 90 deployment.

91

92 Non-standard Abbreviations and Acronyms

93 CA = Cardiac arrest

94 ICD = Implantable cardioverter-defibrillator

95 IR = Incidence Rate

96 IRR = Incidence Rate Ratio

97 OHCA = Out-of-hospital cardiac arrest

98 SCD = Sudden Cardiac Death

99

100 Introduction

101 While overall and cardiovascular disease mortality rates in Western countries have
102 declined in recent decades^{1,2}, sudden cardiac death (SCD) among young individuals
103 aged ≤ 35 years continues to pose a significant public health challenge associated with
104 vast psychological consequences and a substantial loss of productive years^{3,4}.

105 Previous studies have shown that the incidence rates (IR) of SCD among young
106 individuals range from 1–3 per 100 000 person-years^{5,6}, yet there is limited research on
107 contemporary data, and previous studies on temporal trends have been conflicting^{7–11}.

108 As the causes and circumstances of cardiac arrest are strongly age-dependent¹²,
109 temporal trends in the elderly population cannot reliably be extrapolated to the young.
110 Given the decline in mortality rates over the past decades, contemporary estimates of
111 SCD incidence are crucial for evaluating and implementing specific preventive health
112 initiatives targeting the young.

113 In the current study, we aimed to provide contemporary estimates of the incidence of
114 SCD in the young aged 1–35 years and evaluate the temporal trends from 2000–2019 in
115 relation to changes in out-of-hospital cardiac arrest (OHCA) patterns and implantable
116 cardioverter defibrillator (ICD) implantations. Furthermore, we aimed to identify
117 subgroups of the SCD population, in which current preventive strategies have had less
118 impact and where targeted preventive initiatives could be beneficial.

119 Methods

120 This nationwide observational study complies with the STROBE (Strengthening the
121 Reporting of Observational Studies in Epidemiology) guidelines for observational
122 studies.

123 Data availability

124 Data are owned by a third party, and the authors do not have the right to share data;
125 however, upon request, the authors will help in applying to the third party for approval
126 of data sharing.

127 Data sources

128 All Danish citizens are assigned a unique civil registration number, which allows data
129 linkage at the individual level across the administrative registries in Denmark. These
130 registers are government-maintained and comprise longitudinally collected
131 administrative and health-care data¹³.

132 Information from the following registries was included: *The Danish Civil Registration*
133 *System* holds information on sex, migration, and vital status and was used to identify
134 the study population¹³. *The Danish Register of Causes of Death* holds information on
135 the causes and circumstances of all deaths in Denmark¹⁴. *The National Patient Registry*
136 holds information on all hospital encounters and procedures (in-patient since 1978 and
137 out-patient since 1995) and was used to identify comorbidities and ICD
138 implantations¹⁵. *The Danish National Prescription Registry* holds information on

139 prescriptions redeemed at Danish pharmacies since 1995 and was used to identify
140 comorbidities and comedication¹⁶.

141 Additional data sources were a clinical database containing detailed information on all
142 young SCD aged 1–35 in Denmark from 2000–2019⁶ , and the *Danish Cardiac Arrest*
143 *Registry*, which comprises information on all out-of-hospital cardiac arrests (OHCA) in
144 Denmark since 2001 with attempted resuscitation by emergency medical services¹⁷ .

145 [Study population and characteristics](#)

146 All individuals aged 1–35 years living in Denmark during 2000–2019 were included. The
147 annual at-risk population was identified on 1 January of each year (index date).

148 SCD cases were identified through a multi-source approach, which has previously been
149 described in detail^{6,18} . Adjudication was based on manual examination of all death
150 certificates, autopsy reports, and discharge summaries preceding death during the
151 study period. SCD was defined as the *sudden, unexpected death of presumed cardiac*
152 *origin that occurs within 1 hour of symptom onset in witnessed cases and within 24*
153 *hours of last seen alive and well in unwitnessed cases*¹⁹ .

154 To contextualize the trends in SCD, we examined trends in 1) survival and bystander
155 interventions in all OHCA aged 1–35 registered in the Danish Cardiac Arrest Registry
156 from 2001-2019 and 2) all ICD implantations registered during the study period in
157 individuals aged 1–35. ICD implantations were identified by procedural codes from the
158 National Patient Registry (ICD-10 code: BFCB0) and subsequently categorized as either

159 primary prophylactic (no previous record of a cardiac arrest) or secondary prophylactic
160 (in patients with a previous cardiac arrest).

161 Comorbidities were identified from the *Danish National Patient Registry* as any hospital
162 contact with a given diagnosis in the ten years preceding the index date; additionally,
163 hypertension, diabetes, and psychiatric disease were identified by recent co-
164 medication^{20,21}. *Any comorbidity* was defined as the presence of hypertension,
165 cardiovascular disease (CVD), chronic kidney disease (CKD), diabetes, COPD, epilepsy,
166 and psychiatric disease (see *Suppl. Table 1* for definitions of comorbidity). Information
167 on comorbidities was available until 2018.

168 [Statistical analyses](#)

169 The study period was divided into 4-year intervals (2000-2003, 2004-2007, 2008-2011,
170 2012-2015, and 2016-2019) to compare characteristics over time. For descriptive
171 statistics, categorical variables were presented as count and percentages and
172 continuous variables as median and interquartile range (IQR). Temporal trends in
173 continuous variables were assessed with linear regression and presented as 20-year
174 absolute change, and in categorial variables with logistic regression with year as a
175 covariate and presented as 20-year relative risk.

176 IR were calculated as the ratio between mortality counts and the appropriate
177 background population with confidence intervals calculated by Poisson's exact method.
178 Annual IR were standardized on age and sex by direct standardization, using 5-year age

179 groups and the average Danish population throughout the study period as the standard
180 population. Confidence intervals for directly standardized incidence rates (DSIR) were
181 calculated based on the gamma distribution²². Temporal trends in DSIR were calculated
182 as the percentage change annualized (PCA) by fitting log-linear models to the DSIR,
183 using weighted least square regression²³. PCA values were compared by a Wald test of
184 the log-linear models.

185 A two-sided p-value of 5% was considered significant. All calculations were performed
186 in R v. 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria) using the
187 following packages: *data.table*, *targets*, *tidyverse*, *heaven*, and *gtsummary*.

188 Ethics

189 This study complies with the Helsinki Declaration and was approved by the Regional
190 Data Committee (P-2019-813 and P-2019-523). Registry-based studies on deidentified
191 data are exempt from ethical approvals in Denmark. Due to data regulations, counts
192 below four have been masked (≤ 3) throughout the manuscript.

193

194 Results

195 During the 20-year study period, 4 274 630 unique individuals were observed for 47.5
196 million person-years (PY). In total, 15 186 deaths occurred, of which 1 057 (7%) were
197 categorized as SCD.

198 Trends in population characteristics

199 The average population in Denmark aged 1–35 was 2.38 mill (median age: 18 years
200 [IQR 10–27], 51% male), and both population size, age, and sex distribution remained
201 stable throughout the study (*Suppl. Table 2*). While the overall comorbidity burden was
202 low, the prevalence of most comorbidities increased annually. Notably, the prevalence
203 of individuals with a previous cardiac arrest or an ICD increased significantly during the
204 study period (estimated 20-year RR: 8.05 ($p < 0.001$) and 11.03 ($p < 0.001$), respectively).
205 Clinical characteristics of the 1 057 SCD (median age: 29 [IQR 22–33], 69% male)
206 stratified by time period are shown in *Table 1*. Throughout the study period, there was
207 a trend towards a higher proportion of male sex (estimated 20-year RR: 1.13, $p =$
208 0.085). The prevalence of CVD remained constant (15%, p for trend = 0.55). The
209 autopsy rate was stable at 67% (p for trend 0.64), and no substantial changes in causes
210 of death were observed. The proportion of unwitnessed SCD increased by 79% during
211 the study period (estimated 20-year RR: 1.79, $p < 0.001$).

212 SCD Incidence rates and temporal trends

213 SCD Incidence rates are presented in *Table 2*. The overall SCD IR throughout the entire
214 study period was 2.2 per 100 000 PY (95%CI 2.1-2.4). Crude SCD rates decreased from
215 2.89 per 100 000 PY (95%CI 2.56–3.24) in 2000–2003 to 1.67 (95%CI 1.42–1.94) per
216 100 000 PY in 2016–2019. After sex- and age adjustment, the annual decline
217 (percentage change annualized [PCA]) was -3.31% (95%CI -4.20; -2.42), accumulating to

218 a 49.0% (95%CI 38.7–57.6) reduction in the SCD incidence over the 20-year period
219 (*Figure 1*).

220 We observed marked differences in SCD incidence according to sex and witnessed
221 status. Males were at considerably higher risk of SCD (IRR: 2.2 [95%CI 1.9–2.5,
222 $p < 0.001$]), and there was a trend towards an increasing discrepancy between the sexes
223 throughout the study period, illustrated by a 1.9% lower PCA in males compared to
224 females (p for difference = 0.052) (*Figure 2A*). The incidence of witnessed SCD
225 decreased significantly with a PCA of -7.03% (95%CI -8.57; -5.48). Contrarily, we
226 observed no difference in the incidence of unwitnessed SCD (PCA -0.09% [95%CI –
227 1.48;1.31])(*Figure 2B*).

228 Out-of-hospital cardiac arrest

229 From 2001–2019, 2 256 OHCA in individuals aged 1–35 years were registered (median
230 age 25 [IQR 19–31], 70% male sex). Comparing the first and the last time periods, we
231 observed increasing proportions of witnessed OHCA (28% to 39%, $p < 0.001$), bystander
232 cardiopulmonary resuscitation (CPR) (30% to 79%, $p < 0.001$), bystander defibrillation
233 (1.8% to 7.7%, $p < 0.001$) and 30-day survival (3.9% to 28%, $p < 0.001$) (*Figure 3*). Overall,
234 OHCA characteristics were similar between both sexes except for females being
235 younger (24 vs 26 years, $p = 0.014$) and OHCA in women more often occurring in
236 private residences (67% vs 56%, $p < 0.001$). 30-day survival was significantly better
237 among females (22% vs 16%, $p < 0.001$). When temporal changes in OHCA

238 characteristics were assessed, bystander CPR and defibrillation rates improved
239 markedly more among women and surpassed the rates among males (*Suppl Table 3*).

240 ICD implantation

241 During the 20-year study period, 606 ICDs (406 primary prevention, 200 secondary
242 prevention) were implanted in individuals aged 1–35 years (*Figure 4*). The ICD-
243 implantation rate doubled from 73 implantations in 2000-2003 (IR 0.76 per 100 000 PY)
244 to 150 in 2016-2019 (IR 1.55 per 100 000 PY), and the proportion of secondary
245 preventive ICDs increased from 19% to 38%.

246

247 Discussion

248 This longitudinal, study provides contemporary nationwide incidence estimates for SCD
249 based on a large cohort of young SCD cases aged 1–35 years in Denmark. The study's
250 principal findings include a significant decrease in the incidence of SCD (49% over the
251 last 20 years), a substantially 7-fold improved survival following OHCA in young
252 individuals and higher rates of ICD implantation. We believe this is among the first
253 studies to contextualize the trends in SCD to OHCA survival and ICD implantations in
254 young individuals. Notably, the study provides an up-to-date overview of the
255 epidemiology of SCD with potential implications for future preventive initiatives to
256 reduce SCD.

257 Incidence rates of SCD

258 The reported IR of 1.67 per 100 000 PY in the most recent time period (2016–2019) is
259 comparable to the IR reported in the literature^{5,10,24,25}. Direct cross-study comparison of
260 incidence rates is difficult due to vast differences in methodology and study
261 populations. Our multi-source identification of SCD, based on all deaths in Denmark
262 from 2000–2019, reduces the risk of selection bias typically associated with
263 epidemiological studies on selected populations (autopsy cohorts) or ICD-codes from
264 death certificates, and we believe it offers the most accurate estimate of the true
265 burden of SCD.

266 More importantly, we observed a 3.3% annual decline in SCD incidence, accumulating
267 to a 49% reduction in SCD over the 20-year study period. All observed subgroups
268 exhibited declining rates, apart from unwitnessed SCD, where the IR remained stable.
269 Our group has previously reported temporal trends in young SCD from 2000-2009⁹, and
270 the trend has continued to decline at a comparable rate over the past decade. Similar
271 findings have been reported in young SCD^{7,26}, SCD in all ages^{2,11}, and cardiovascular
272 mortality², supporting an overall trend of declining SCD mortality.

273 Improved survival after OHCA

274 The reduction in SCD mortality is multifactorial, but improved survival after OHCA is
275 among the most important contributors. Several strategies to improve OHCA survival
276 have been implemented in Denmark in the last decades, including widespread CPR

277 training, lay-person activation ("Heart runner" program), and increased public
278 automated external defibrillators (AED) availability^{27,28}, and the effects of these
279 community-based interventions on survival are well documented^{29,30}. During the study
280 period, survival after OHCA in individuals aged 1–35 increased from 4% to 28%,
281 concomitantly with an increase in bystander CPR and defibrillation to approximately
282 80% and 8%, respectively. Although a significant proportion of OHCA in young
283 individuals are non-cardiac³¹, this improved survival translates directly into a lower SCD
284 incidence. Although the rate of bystander defibrillation increased significantly during
285 the study period, AEDs were only used in 8% of the young OHCA victims. The low rate
286 was likely due to most arrests occurring in private homes, where rates of bystander
287 defibrillation remain low¹⁷. Early bystander defibrillation is a key prognostic factor for
288 survival²⁹, and further improvement in the rate of bystander AED use is critical in
289 improving survival.

290 The proportion of female SCD decreased during the study period, although just missing
291 statistical significance ($p = 0.058$) – we think this is likely an issue of statistical power.
292 Similar findings have been described in studies of both younger¹⁰ and older¹¹ SCD
293 cohorts, and higher OHCA survival rates have been reported in females^{32,33}. In the
294 current study, bystander CPR and defibrillation rates — key prognostic markers for
295 improved survival — increased among both sexes, but the increase was markedly
296 higher among women, where the rates even surpassed those among males. This
297 difference likely contributed to the observed discrepancy between sexes in OHCA

298 survival and SCD incidence. The equal CPR and defibrillation rates in recent years
299 contrast previous reports of OHCA in females^{33,34} and could reflect differences in study
300 populations and characteristics (younger age in the current study) or cultural
301 differences towards resuscitation attempts in younger women.

302 [Prevention of SCD and identification of high-risk individuals](#)

303 ICD implantation is a key component in preventing SCD in high-risk patients, as it
304 significantly reduces the risk of arrhythmic death^{19,35}. During the study period, the
305 prevalence of ICDs in the young general population increased more than 10-fold, which
306 is likely multifactorial. First, as the number of OHCA survivors increases, more patients
307 will be eligible for ICD implantation. Causes of OHCA among young individuals differ
308 from the elderly with more structural and inherited cardiac disease^{12,18}, in whom
309 secondary ICD implantation is more likely. Accordingly, we observed an increased ICD
310 implantation in cardiac arrest survivors. Similar findings have been reported in Western
311 Australia, where ICD implantation rates increased 15-fold from 1995 to 2009¹¹,
312 paralleled by improved OHCA survival. Second, substantial improvements in our
313 understanding of the pathophysiology and genetics underlying inherited cardiac
314 diseases have improved risk stratification significantly. Combined with systematic family
315 cascade screening of relatives to SCA/SCD victims, in whom the risk of inherited cardiac
316 diseases is significantly higher³⁶, we likely identify more individuals at risk of SCD who
317 are eligible for a primary preventive ICD.

318 For both primary and secondary prevention ICDs, whether mortality reduction is due to
319 the actual ICD, improved medical care and awareness in patients with an ICD
320 (performance bias), or a combination remains speculative. However, a recent study by
321 Ruwald et al.²⁸ found a significant decline in the delivery of appropriate shocks in
322 patients with secondary ICDs during the last decade, and thus fewer who seem to
323 benefit from their ICD. As young individuals with an ICD have a high lifetime risk of
324 device-related complications³⁷, this finding highlights the need for better pre-
325 implantation risk stratification and identification of those who may benefit from an ICD,
326 in order to reduce unnecessary implantations.

327 A surprising finding of this study was the discrepancy in SCD trends between witnessed
328 and unwitnessed SCD. As we only observed declining rates of SCD that were witnessed,
329 the proportion of unwitnessed SCD increased by 79% to approximately three in four,
330 which is markedly higher than previously reported^{38,39}. Previous studies have identified
331 key differences between witnessed and unwitnessed SCD — e.g. more unexplained
332 deaths, higher proportion of males, different comorbidity profiles and more frequent
333 death during sleep among unwitnessed SCD^{38,40}. Therefore, this shift has substantial
334 implications for the epidemiology of SCD, and future preventive measures must reflect
335 this change as strategies targeting OHCA may have a limited impact on preventing
336 unwitnessed SCD. Prevention of SCD that occur unwitnessed or during sleep is
337 particularly difficult, as timely recognition and intervention is hindered and survival
338 chances thus dramatically lower. However, connected devices —e.g., smart watches

339 and speakers— are increasingly capable of identifying malignant arrhythmias and
340 alerting first responders or family members^{41,42}. Although these solutions are still in
341 their infancy, they present an exciting opportunity to monitor high-risk patients and
342 lower mortality^{43,44}.

343 Study limitations

344 We acknowledge several limitations of our study. First, the observational nature
345 imposes limitations on the assertions of causality, and interpretation should be made
346 with caution. Second, changes in coding practices, diagnostic criteria, and procedural
347 indications during the 20-year study period may have impacted the observed trends.
348 However, this would primarily affect estimates of comorbidity and have less impact on
349 SCD rates due to the multi-source identification of SCD. Similarly, the OHCA registry has
350 undergone administrative changes during the study period with improved capture due
351 to electronic registration since 2016. However, the improving trend in survival was
352 observed throughout the entire study period, indicating that the underreporting of
353 OHCA cases was likely at random with little effect on our estimates. We had no
354 information about ICD therapies, which could have added further insight into the value
355 if increased ICD implantation. Last, information on modifiable risk factors (BMI,
356 smoking, alcohol intake, activity level) that may influence disease patterns was not
357 available from the national registries.

358

359 Conclusion

360 Over the past 20 years, there has been a 49% decrease in the incidence of SCD in young
361 individuals aged 1–35 in Denmark. Steep inclines in both ICD implantations and survival
362 rates of cardiac arrest victims paralleled the decline. However, we observed no change
363 in the incidence of unwitnessed SCD, and preventive efforts need to address this issue,
364 e.g., by concentrating on near-term prevention.

365

366 Acknowledgements

367 The authors acknowledge the Danish Clinical Quality Program – National Clinical
368 Registries (RKKP). for making it possible to work with data from the Danish Cardiac
369 Arrest Registry.

370

371 Sources of funding

372 This study was supported by an internal grant from the University of Copenhagen,
373 Denmark. However, the university did not influence the study design, data acquisition,
374 data analysis, or article preparation or any effect on the publication process.

375

376 Disclosures

377 The other authors report no conflicts of interest.

378

379 Supplemental Material

380 Tables S1–S3

381 References

- 382 1. Wang H, Abbas KM, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, et al. Global
383 age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in
384 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global
385 Burden of Disease Study 2019. *The Lancet* 2020;396:1160–1203. doi:10.1016/S0140-
386 6736(20)30977-6.
- 387 2. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease
388 mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study.
389 *Circulation* 2004;110:522–527. doi:10.1161/01.CIR.0000136993.34344.41.
- 390 3. Empana J-P, Lerner I, Valentin E, Folke F, Böttiger B, Gislason G, et al. Incidence of Sudden
391 Cardiac Death in the European Union. *Journal of the American College of Cardiology*
392 2022;79:1818–1827. doi:10.1016/j.jacc.2022.02.041.
- 393 4. Waldmann V, Karam N, Bougouin W, Sharifzadehgan A, Dumas F, Narayanan K, et al. Burden of
394 Coronary Artery Disease as a Cause of Sudden Cardiac Arrest in the Young. *Journal of the*
395 *American College of Cardiology* 2019;73:2118–2120. doi:10.1016/j.jacc.2019.01.064.
- 396 5. Couper K, Putt O, Field R, Poole K, Bradlow W, Clarke A, et al. Incidence of sudden cardiac death
397 in the young: a systematic review. *BMJ Open* 2020;10:e040815. doi:10.1136/bmjopen-2020-
398 040815.
- 399 6. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al. Nationwide study
400 of sudden cardiac death in persons aged 1–35 years. *European Heart Journal* 2011;32:983–990.
401 doi:10.1093/eurheartj/ehq428.
- 402 7. Vähätalo J, Holmström L, Pakanen L, Kaikkonen K, Perkiömäki J, Huikuri H, et al. Temporal
403 Trends in the Incidence and Characteristics of Sudden Cardiac Death among Subjects under 40
404 Years of Age in Northern Finland during 1998–2017. *Cardiology* 2022;147:328–331.
405 doi:10.1159/000522554.
- 406 8. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in Sudden Cardiovascular
407 Death in Young Competitive Athletes After Implementation of a Preparticipation Screening
408 Program n.d.
- 409 9. Lynge TH, Nielsen JL, Blanche P, Gislason G, Torp-Pedersen C, Winkel BG, et al. Decline in
410 incidence of sudden cardiac death in the young: a 10-year nationwide study of 8756 deaths in
411 Denmark. *EP Europace* 2019;21:909–917. doi:10.1093/europace/euz022.
- 412 10. Wisten A, Krantz P, Stattin E-L. Sudden cardiac death among the young in Sweden from 2000 to
413 2010: an autopsy-based study. *Europace* 2016;euw249. doi:10.1093/europace/euw249.
- 414 11. Feng J-L, Nedkoff L, Knuiman M, Semsarian C, Ingles J, Briffa T, et al. Temporal Trends in Sudden
415 Cardiac Death From 1997 to 2010: A Data Linkage Study. *Heart, Lung and Circulation*
416 2017;26:808–816. doi:10.1016/j.hlc.2016.11.021.

- 417 12. Lynge TH, Nielsen JL, Risgaard B, Werf C van der, Winkel BG, Tfelt-Hansen J. Causes of sudden
418 cardiac death according to age and sex in persons aged 1–49 years. *Heart Rhythm* 2023;20:61–
419 68. doi:10.1016/j.hrthm.2022.08.036.
- 420 13. Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish
421 health care system and epidemiological research: from health care contacts to database
422 records. *CLEP* 2019;Volume 11:563–591. doi:10.2147/CLEP.S179083.
- 423 14. Helweg-Larsen K. The Danish Register of Causes of Death. *Scand J Public Health* 2011;39:26–29.
424 doi:10.1177/1403494811399958.
- 425 15. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish
426 National Patient Registry: a review of content, data quality, and research potential. *Clin
427 Epidemiol* 2015;7:449–490. doi:10.2147/CLEP.S91125.
- 428 16. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data
429 Resource Profile: The Danish National Prescription Registry. *International Journal of
430 Epidemiology* 2017;46:798–798f. doi:10.1093/ije/dyw213.
- 431 17. Danish Cardiac Arrest Registry. Danish Cardiac Arrest Registry: Executive Summary of the
432 Annual Report 2022. n.d.
- 433 18. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al. Nationwide burden of
434 sudden cardiac death: A study of 54,028 deaths in Denmark. *Heart Rhythm* 2021.
435 doi:10.1016/j.hrthm.2021.05.005.
- 436 19. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC
437 Guidelines for the management of patients with ventricular arrhythmias and the prevention of
438 sudden cardiac death: Developed by the task force for the management of patients with
439 ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of
440 Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital
441 Cardiology (AEPC). *European Heart Journal* 2022;43:3997–4126.
442 doi:10.1093/eurheartj/ehac262.
- 443 20. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk
444 stratification schemes for predicting stroke and thromboembolism in patients with atrial
445 fibrillation: nationwide cohort study. *BMJ* 2011;342:d124. doi:10.1136/bmj.d124.
- 446 21. Lynge TH, Svane J, Pedersen-Bjergaard U, Gislason G, Torp-Pedersen C, Banner J, et al. Sudden
447 cardiac death among persons with diabetes aged 1–49 years: a 10-year nationwide study of 14
448 294 deaths in Denmark. *European Heart Journal* 2020;41:2699–2706.
449 doi:10.1093/eurheartj/ehz891.
- 450 22. Fay MP, Feuer EJ. CONFIDENCE INTERVALS FOR DIRECTLY STANDARDIZED RATES: A METHOD
451 BASED ON THE GAMMA DISTRIBUTION. *Statist Med* 1997;16:791–801. doi:10.1002/(SICI)1097-
452 0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#.

- 453 23. Fay MP, Tiwari RC, Feuer EJ, Zou Z. Estimating Average Annual Percent Change for Disease Rates
454 without Assuming Constant Change. *Biometrics* 2006;62:847–854. doi:10.1111/j.1541-
455 0420.2006.00528.x.
- 456 24. Bagnall RD, Weintraub RG, Ingles J, Duflou J, Yeates L, Lam L, et al. A Prospective Study of
457 Sudden Cardiac Death among Children and Young Adults. *N Engl J Med* 2016;374:2441–2452.
458 doi:10.1056/NEJMoa1510687.
- 459 25. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden of sudden
460 cardiac death: Multiple source surveillance versus retrospective death certificate-based review
461 in a large U.S. community. *Journal of the American College of Cardiology* 2004;44:1268–1275.
462 doi:10.1016/j.jacc.2004.06.029.
- 463 26. Ha FJ, Han H-C, Sanders P, Fendel K, Teh AW, Kalman JM, et al. Sudden Cardiac Death in the
464 Young. *Circulation: Cardiovascular Quality and Outcomes* 2020;13:e006470.
465 doi:10.1161/CIRCOUTCOMES.119.006470.
- 466 27. Wissenberg M, Lippert FK, Folke F, Weeke P, Hansen CM, Christensen EF, et al. Association of
467 National Initiatives to Improve Cardiac Arrest Management With Rates of Bystander
468 Intervention and Patient Survival After Out-of-Hospital Cardiac Arrest. *JAMA* 2013;310:1377–
469 1384. doi:10.1001/jama.2013.278483.
- 470 28. Hansen CM, Lippert FK, Wissenberg M, Weeke P, Zinckernagel L, Ruwald MH, et al. Temporal
471 trends in coverage of historical cardiac arrests using a volunteer-based network of automated
472 external defibrillators accessible to laypersons and emergency dispatch centers. *Circulation*
473 2014;130:1859–1867. doi:10.1161/CIRCULATIONAHA.114.008850.
- 474 29. Kragholm K, Wissenberg M, Mortensen RN, Hansen SM, Malta Hansen C, Thorsteinsson K, et al.
475 Bystander Efforts and 1-Year Outcomes in Out-of-Hospital Cardiac Arrest. *N Engl J Med*
476 2017;376:1737–1747. doi:10.1056/NEJMoa1601891.
- 477 30. Simmons KM, Mclsaac SM, Ohle R. Impact of community-based interventions on out-of-hospital
478 cardiac arrest outcomes: a systematic review and meta-analysis. *Scientific Reports* 2023;13.
479 doi:10.1038/s41598-023-35735-y.
- 480 31. Paratz ED, van Heusden A, Zentner D, Morgan N, Smith K, Thompson T, et al. Causes,
481 circumstances, and potential preventability of cardiac arrest in the young: insights from a state-
482 wide clinical and forensic registry. *EP Europace* 2022;24:1933–1941.
483 doi:10.1093/europace/euac141.
- 484 32. Kitamura T, Iwami T, Nichol G, Nishiuchi T, Hayashi Y, Nishiyama C, et al. Reduction in incidence
485 and fatality of out-of-hospital cardiac arrest in females of the reproductive age. *European Heart*
486 *Journal* 2010;31:1365–1372. doi:10.1093/eurheartj/ehq059.
- 487 33. Bougouin W, Mustafic H, Marijon E, Murad MH, Dumas F, Barbouttis A, et al. Gender and
488 survival after sudden cardiac arrest: A systematic review and meta-analysis. *Resuscitation*
489 2015;94:55–60. doi:10.1016/j.resuscitation.2015.06.018.

- 490 34. Blom MT, Oving I, Berdowski J, van Valkengoed IGM, Bardai A, Tan HL. Women have lower
491 chances than men to be resuscitated and survive out-of-hospital cardiac arrest. *European Heart*
492 *Journal* 2019;40:3824–3834. doi:10.1093/eurheartj/ehz297.
- 493 35. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck K-H, Zipes DP, et al. Meta-analysis of the
494 implantable cardioverter defibrillator secondary prevention trials. *European Heart Journal*
495 2000;21:2071–2078. doi:10.1053/euhj.2000.2476.
- 496 36. Ranthe MF, Winkel BG, Andersen EW, Risgaard B, Wohlfahrt J, Bundgaard H, et al. Risk of
497 cardiovascular disease in family members of young sudden cardiac death victims. *European*
498 *Heart Journal* 2013;34:503–511. doi:10.1093/eurheartj/ehs350.
- 499 37. Olde Nordkamp LRA, Wilde AAM, Tijssen JGP, Knops RE, van Dessel PFHM, de Groot JR. The ICD
500 for Primary Prevention in Patients With Inherited Cardiac Diseases. *Circulation: Arrhythmia and*
501 *Electrophysiology* 2013;6:91–100. doi:10.1161/CIRCEP.112.975268.
- 502 38. Svane J, Lynge TH, Hansen CJ, Risgaard B, Winkel BG, Tfelt-Hansen J. Witnessed and
503 unwitnessed sudden cardiac death: a nationwide study of persons aged 1–35 years. *EP*
504 *Europace* 2021;23:898–906. doi:10.1093/europace/euab017.
- 505 39. Jayaraman R, Reinier K, Nair S, Aro AL, Uy-Evanado A, Rusinaru C, et al. Risk Factors of Sudden
506 Cardiac Death in the Young. *Circulation* 2018;137:1561–1570.
507 doi:10.1161/CIRCULATIONAHA.117.031262.
- 508 40. Hansen CJ, Svane J, Lynge TH, Stampe NK, Bhardwaj P, Torp-Pedersen C, et al. Differences
509 among young unwitnessed sudden cardiac death, according to time from last seen alive:
510 Insights from a 15-year nationwide study. *Heart Rhythm* 2023;1504–1509.
511 doi:10.1016/j.hrthm.2023.07.005.
- 512 41. Bayoumy K, Gaber M, Elshafeey A, Mhaimed O, Dineen EH, Marvel FA, et al. Smart wearable
513 devices in cardiovascular care: where we are and how to move forward. *Nat Rev Cardiol*
514 2021;18:581–599. doi:10.1038/s41569-021-00522-7.
- 515 42. Garcia R, Warming PE, Narayanan K, Defaye P, Guedon-Moreau L, Blangy H, et al. Dynamic
516 changes in nocturnal heart rate predict short-term cardiovascular events in patients using the
517 wearable cardioverter-defibrillator: from the WEARIT-France cohort study. *EP Europace*
518 2023;25:eua062. doi:10.1093/europace/eua062.
- 519 43. Marijon E, Narayanan K, Smith K, Barra S, Basso C, Blom MT, et al. The Lancet Commission to
520 reduce the global burden of sudden cardiac death: a call for multidisciplinary action. *The Lancet*
521 2023;402:883–936. doi:10.1016/S0140-6736(23)00875-9.
- 522 44. Marijon E, Garcia R, Narayanan K, Karam N, Jouven X. Fighting against sudden cardiac death:
523 need for a paradigm shift—Adding near-term prevention and pre-emptive action to long-term
524 prevention. *European Heart Journal* 2022;43:1457–1464. doi:10.1093/eurheartj/ehab903.

526 Tables and figures

527

528 Legends

529 **Table 1:** Characteristics of all sudden cardiac death (SCD) cases, stratified by time
530 period.

531 **Table 2:** Incidence rates and temporal trends of sudden cardiac death (SCD) in the
532 young aged 1–35

533 **Figure 1:** Temporal trends in sudden cardiac death (SCD) incidence from 2000–2019

534 **Figure 2:** Temporal trends in sudden cardiac death (SCD) incidence, by sex (panel A) and
535 witnessed status (panel B).

536 **Figure 3:** Temporal trends in bystander cardiopulmonary resuscitation (CPR) (Panel A)
537 and cardiac arrest survival (panel B) in the young aged 1–35.

538 **Figure 4:** Temporal trends in implantable cardioverter defibrillator implantation in the
539 young aged 1–35. Panel A: Implantations of primary and secondary preventive ICD.
540 Panel B: Trends in the proportion of secondary preventive ICD of all ICDs implanted.

541

542 Table 1: Characteristics of all sudden cardiac death (SCD) cases, stratified by time period.

Characteristic ¹	Overall N = 1 057	2000-2003 N = 277	2004-2007 N = 247	2008-2011 N = 203	2012-2015 N = 169	2016-2019 N = 161	Estimated 20-year RR	95%CI for RR
Male sex	733 (69%)	173 (62%)	183 (74%)	144 (71%)	113 (67%)	120 (75%)	1.13	0.99–1.29
Age	29 (22–33)	29 (23–33)	29 (22–33)	29 (22–34)	28 (22–33)	29 (22–32)	-0.18 yr	-1.90–1.54
<u>Comorbidity</u>								
Any of the below	414 (39%)	75 (27%)	92 (37%)	87 (43%)	89 (53%)	71 (44%)	1.62	1.28–2.02
HT	51 (5%)	14 (5%)	12 (5%)	9 (4%)	5 (3%)	11 (7%)	1.12	0.44–2.82
CVD	167 (16%)	44 (16%)	45 (18%)	29 (14)	24 (14%)	25 (16%)	0.86	0.53–1.39
IHD	22 (2%)	7 (3%)	8 (3%)	<= 3	<= 3	5 (3%)	0.63	0.14–2.66
Prev. MI	14 (1%)	4 (1%)	5 (2%)	<= 3	<= 3	5 (3%)	1.34	0.21–8.04
Prev. CA	9 (1%)	<= 3	4 (2%)	<= 3	<= 3	<= 3	0.44	0.033–4.32
AF	19 (2%)	6 (2%)	<= 3	<= 3	5 (3%)	<= 3	0.98	0.20–4.55
CM	32 (3%)	11 (4%)	8 (3%)	7 (3%)	<= 3	<= 3	0.41	0.11–1.37
Conduct. disease	44 (4%)	10 (4%)	11 (5%)	6 (3%)	9 (5%)	8 (5%)	1.33	0.48–3.58
Congenital HD	66 (6%)	17 (6%)	17 (7%)	13 (6%)	11 (7%)	8 (5%)	0.80	0.35–1.81
ICD	8 (1%)	<= 3	<= 3	<= 3	<= 3	4 (3%)	39.50	2.91–1030
Epilepsy	143 (14%)	15 (5%)	23 (9%)	36 (18%)	38 (22%)	31 (19%)	4.48	2.69–7.50
Psychiatric disease	193 (18%)	25 (9%)	37 (15%)	42 (20%)	53 (31%)	36 (22%)	2.70	2.01–4.69
Diabetes	44 (4%)	11 (4%)	15 (6%)	9 (4%)	4 (2Q%)	5 (3%)	0.64	0.22–1.75
<u>Death-related circumstances</u>								
Unwitnessed SCD	577 (59%)	120 (47%)	112 (51%)	112 (58%)	123 (74%)	110 (73%)	1.79	1.51–2.12
Dead in sleep	322 (36%)	78 (33%)	75 (36%)	60 (35%)	47 (35%)	62 (44%)	1.32	0.97–1.77
Sports related	58 (5.6%)	16 (5.8%)	15 (6.1%)	14 (6.9%)	6 (3.6%)	7 (4.7%)	0.80	0.33–1.92
Autopsy performed	707 (67%)	182 (66%)	166 (67%)	148 (73%)	107 (63%)	104 (65%)	0.96	0.83–1.12

¹Data are n (%) and median (Q1-Q3).


AF: Atrial fibrillation, CA: Cardiac arrest, CM: Cardiomyopathy, CVD: Cardiovascular disease, HT: Hypertension, ICD: Implantable cardioverter defibrillator, IHD: Ischemic heart disease, MI: Myocardial infarction, RR = relative risk, SCD: Sudden cardiac death

543 Table 2: Incidence rates and temporal trends of sudden cardiac death (SCD) in the young aged 1–35

	SCD cases	Person-years	Crude incidence estimates				Adjusted annual changes	
			Crude IR	IR 95%CI	IRR	IRR 95%CI	PCA (%)	PCA 95%CI
All SCD	1 057	47.5 million	2.2	2.1-2.4	-	-	-3.31	-4.2 to -2.42
By groups								
<u>Time period</u>								
2000-2003	277	9.6 million	2.89	2.56-3.24	-	-	-	-
2004-2007	247	9.4 million	2.6	2.3-3.0	0.91	0.77-1.1	-	-
2008-2011	203	9.4 million	2.2	1.9-2.5	0.75	0.62-0.89	-	-
2012-2015	169	9.4 million	1.8	1.5-2.1	0.62	0.51-0.75	-	-
2016-2019	161	9.7 million	1.67	1.42-1.94	0.58	0.47-0.7	-	-
<u>Sex</u>								
Female	324	23.3 million	1.4	1.2-1.5	-	-	-4.66	-6.17 to -3.14
Male	733	24.2 million	3.0	2.8-3.3	2.2	1.9-2.5	-2.73	-3.95 to -1.50
<u>Age</u>								
1-18	175	23.8 million	0.74	0.63-0.85	-	-	-4.7	-7.5 to -1.9
19-35	882	23.7 million	3.70	3.50-4.00	5.1	4.3-6.0	-2.8	-3.9 to -1.8
<u>Witnessed status</u>								
Witnessed	406	47.5 million	0.85		-	-	-7.03	-5.46 to -2.71
Unwitnessed	651	47.5 million	1.37		1.6	-	-0.09	-1.48 to 1.31


CI: Confidence interval, IR: Incidence rates, IRR: Incidence rate ratio, PCA: Percentage change annualized, SCD: Sudden cardiac death

544 Figure 1: Temporal trends in SCD incidence from 2000–2019




549 Figure 2: Temporal trends in SCD incidence, by sex and witnessed status

550



553 Figure 3: Temporal trends in OHCA survival and bystander CPR in the young
554 aged 1–35
555




556

557

558

559

560 Figure 4: Temporal trends in ICD implantations in the young aged 1–35



561

562 Suppl. Table 1: Definitions of comorbidities and ICD-codes used to define
 563 diseases

564 Hypertension	<i>Prescription claims of two of the following drugs w/i 180 days:</i> ACE/ARB, Beta blockers, Loop diuretics, MRA, ARNI, Thiazides
Cardiovascular disease	ICD-10: DI110, DI130, DI20-51, DQ20-26 ICD-8: 410-414, 425, 427, 428, 746, 747
Ischemic heart disease	ICD-10: DI20-25 ICD-8: 410-414
Prev. MI	ICD-10: DI21-23, DI252, ICD-8: 410-411
Prev. CA	DI46
AF	ICD-10: DI48 ICD-8:42793, 42794
Cardiomyopathy	ICD-10: DI42-DI43 ICD-8: 425
Conduction diseases	ICD10: DI44-45, DI47, DI49
Congenital HD	ICD-10: DQ20-26 ICD-8: 746, 747
ICD	ICD-10: DZ950A, DZ950C, DZ950D, UFYA31", ZZ4051, BFCB, KFPG
Epilepsy	ICD-10: DG40-41 ICD-8: 345
Psychiatric disease	ICD10: DF101-109, DF111-119, DF121-129, DF131-139, DF141-149, DF151-159, DF161, DF171-179, DF181-189, DF191-199, DF20-99 ICD8: 29,300-301, 305-315 <u>OR</u> <i>Prescription claims of any antipsychotic drug w/i 180 days</i>
Diabetes	ICD-10: DE10-14 ICD-8: 249, 250 <u>OR</u> <i>Prescription claims of one of the following drugs w/i 180 days:</i> Insulin, Metformin, Biguanid, Sulfonylurea, Sulfomid, Thiazolidinidion, DPP4-inhibitor, GLP1-agonist, SGLT2-inhib

565 Suppl. Table 2: Characteristics of the general population, stratified by year

	Overall	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Population	47 512 622	2 414 649	2 403 520	2 392 209	2 375 476	2 360 593	2 351 574	2 347 356	2 347 663	2 350 387	2 354 962
Male sex	24 212 851 (51%)	1 233 010 (51%)	1 226 108 (51%)	1 219 309 (51%)	1 209 652 (51%)	1 201 661 (51%)	1 196 358 (51%)	1 193 712 (51%)	1 193 723 (51%)	1 195 151 (51%)	1 197 905 (51%)
Age	18 (10–27)	20 (9–28)	19 (9–28)	19 (9–28)	19 (9–28)	18 (9–28)	18 (9–28)	18 (9–28)	18 (9–28)	18 (9–27)	18 (9–27)
<u>Comorbidity</u>											
Any	2 661 419 (6%)	98 914 (4%)	100 907 (4%)	103 599 (4%)	105 834 (5%)	108 175 (5%)	110 685 (5%)	113 408 (5%)	118 171 (5%)	122 296 (5%)	126 577 (5%)
Hypertension	57 073 (0.1%)	2 156 (<0.1%)	2 258 (<0.1%)	2 405 (0.1%)	2 485 (0.1%)	2 768 (0.1%)	3 096 (0.1%)	3 195 (0.1%)	3 492 (0.1%)	3 706 (0.2%)	3 811 (0.2%)
CVD	542 145 (1.1%)	20 212 (0.8%)	20 979 (0.9%)	21 923 (0.9%)	22 526 (0.9%)	23 011 (1.0%)	23 425 (1.0%)	23 806 (1.0%)	24 481 (1.0%)	25 152 (1.1%)	25 993 (1.1%)
IHD	34 359 (<0.1%)	1 393 (<0.1%)	1 487 (<0.1%)	1 633 (<0.1%)	1 670 (<0.1%)	1 750 (<0.1%)	1 829 (<0.1%)	1 822 (<0.1%)	1 832 (<0.1%)	1 809 (<0.1%)	1 800 (<0.1%)
Prev. MI	8 464 (<0.1%)	436 (<0.1%)	435 (<0.1%)	459 (<0.1%)	443 (<0.1%)	468 (<0.1%)	468 (<0.1%)	453 (<0.1%)	458 (<0.1%)	457 (<0.1%)	456 (<0.1%)
Prev. CA	3 248 (<0.1%)	59 (<0.1%)	58 (<0.1%)	60 (<0.1%)	62 (<0.1%)	74 (<0.1%)	79 (<0.1%)	83 (<0.1%)	101 (<0.1%)	109 (<0.1%)	115 (<0.1%)
AF	24 152 (<0.1%)	801 (<0.1%)	891 (<0.1%)	971 (<0.1%)	1 058 (<0.1%)	1 093 (<0.1%)	1 117 (<0.1%)	1 156 (<0.1%)	1 210 (<0.1%)	1 239 (<0.1%)	1 269 (<0.1%)
CM	15 285 (<0.1%)	464 (<0.1%)	516 (<0.1%)	560 (<0.1%)	599 (<0.1%)	629 (<0.1%)	667 (<0.1%)	687 (<0.1%)	708 (<0.1%)	741 (<0.1%)	746 (<0.1%)
Cond. def.	157 218 (0.3%)	4 251 (0.2%)	4 772 (0.2%)	5 255 (0.2%)	5 727 (0.2%)	6 181 (0.3%)	6 473 (0.3%)	6 746 (0.3%)	7 034 (0.3%)	7 338 (0.3%)	7 620 (0.3%)
Congenital	263 384 (0.6%)	11 102 (0.5%)	11 138 (0.5%)	11 331 (0.5%)	11 373 (0.5%)	11 308 (0.5%)	11 348 (0.5%)	11 348 (0.5%)	11 664 (0.5%)	11 995 (0.5%)	12 553 (0.5%)
ICD	5 234 (<0.1%)	34 (<0.1%)	47 (<0.1%)	62 (<0.1%)	74 (<0.1%)	105 (<0.1%)	126 (<0.1%)	137 (<0.1%)	152 (<0.1%)	182 (<0.1%)	203 (<0.1%)
Epilepsy	422 613 (0.9%)	22 394 (0.9%)	22 498 (0.9%)	22 483 (0.9%)	22 306 (0.9%)	21 807 (0.9%)	21 622 (0.9%)	21 590 (0.9%)	21 528 (0.9%)	21 335 (0.9%)	21 206 (0.9%)
Psychiatric	1 291 418 (2.7%)	35 763 (1.5%)	37 237 (1.5%)	39 112 (1.6%)	41 240 (1.7%)	43 576 (1.8%)	45 845 (1.9%)	47 594 (2.0%)	51 258 (2.2%)	54 983 (2.3%)	58 932 (2.5%)
Diabetes	262 910 (0.5%)	9 311 (0.5%)	9 419 (0.5%)	9 552 (0.5%)	9 761 (0.5%)	10 204 (0.5%)	10 917 (0.5%)	12 078 (0.5%)	12 938 (0.5%)	13 575 (0.5%)	13 876 (0.5%)
Deaths	15 189	1 080	1 048	1 088	979	952	852	828	843	848	789
SCD	1 057	71	69	66	71	75	67	41	64	51	57

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Est. 20-year RR	95% CI RR
Population	2 356 252	2 357 053	2 355 283	2 356 580	2 362 855	2 369 955	2 392 219	2 409 309	2 425 936	2 428 791	-	-
Male sex	1 198 188 (51%)	1 198 897 (51%)	1 198 593 (51%)	1 199 630 (51%)	1 204 002 (51%)	1 209 250 (51%)	1 222 689 (51%)	1 232 163 (51%)	1 240 838 (51%)	1 242 012 (51%)	1.003	1.003- 1.004
Age	18 (9–27)	18 (9–27)	18 (10–27)	18 (10–26)	18 (10–26)	19 (10–26)	19 (10–27)	19 (10–27)	19 (10–27)	19 (10–27)		
<u>Comorbidity</u>												
Any	131 658 (5.5%)	137 752 (6%)	143 513 (6%)	149 705 (6.5%)	155 353 (6.5%)	160 769 (7%)	166 271 (7%)	171 486 (7%)	176 917 (7.5%)	-	1.87	1.87- 1.88
Hypertensio	3 539 (0.2%)	3 536 (0.2%)	3 356 (0.1%)	3 252 (0.1%)	3 015 (0.1%)	2 763 (0.1%)	2 805 (0.1%)	2 732 (0.1%)	2 703 (0.1%)	-	0.86	0.84- 0.89
CVD	26 795 (1.1%)	27 892 (1.2%)	28 911 (1.2%)	29 919 (1.3%)	30 760 (1.3%)	31 783 (1.3%)	33 053 (1.4%)	34 132 (1.4%)	35 131 (1.4%)	-	1.75	1.73- 1.76
IHD	1 747 (<0.1%)	1 887 (<0.1%)	1 876 (<0.1%)	1 850 (<0.1%)	1 799 (<0.1%)	1 811 (<0.1%)	1 771 (<0.1%)	1 683 (<0.1%)	1 591 (<0.1%)	-	1.02	0.98- 1.06
Prev. MI	430 (<0.1%)	438 (<0.1%)	427 (<0.1%)	409 (<0.1%)	378 (<0.1%)	377 (<0.1%)	391 (<0.1%)	386 (<0.1%)	389 (<0.1%)	-	0.77	0.71- 0.82
Prev. CA	135 (<0.1%)	147 (<0.1%)	180 (<0.1%)	214 (<0.1%)	254 (<0.1%)	274 (<0.1%)	292 (<0.1%)	311 (<0.1%)	329 (<0.1%)	-	8.05	7.06- 9.19
AF	1 291 (<0.1%)	1 288 (<0.1%)	1 307 (<0.1%)	1 359 (<0.1%)	1 356 (<0.1%)	1 400 (<0.1%)	1 389 (<0.1%)	1 379 (<0.1%)	1 387 (<0.1%)	-	1.50	1.44- 1.57
CM	776 (<0.1%)	815 (<0.1%)	843 (<0.1%)	894 (<0.1%)	935 (<0.1%)	934 (<0.1%)	939 (<0.1%)	968 (<0.1%)	987 (<0.1%)	-	1.95	1.85- 2.06
Cond. def.	7 922 (0.3%)	8 232 (0.3%)	8 665 (0.4%)	9 117 (0.4%)	9 498 (0.4%)	9 899 (0.4%)	10 395 (0.4%)	10 832 (0.4%)	11 124 (0.5%)	-	2.39	2.35- 2.44
Congenital	13 036 (0.6%)	13 568 (0.6%)	14 012 (0.6%)	14 358 (0.6%)	14 688 (0.6%)	15 056 (0.6%)	15 532 (0.6%)	15 982 (0.7%)	16 543 (0.7%)	-	1.58	1.55- 1.60
ICD	236 (<0.1%)	268 (<0.1%)	293 (<0.1%)	336 (<0.1%)	398 (<0.1%)	439 (<0.1%)	476 (<0.1%)	551 (<0.1%)	571 (<0.1%)	-	11.03	9.92- 12.27
Epilepsy	20 812 (0.9%)	20 656 (0.9%)	20 656 (0.9%)	20 697 (0.9%)	20 725 (0.9%)	20 541 (0.9%)	20 503 (0.9%)	20 304 (0.8%)	20 307 (0.8%)	-	0.86	0.85- 0.87
Psychiatric	64 161 (2.7%)	69 324 (2.9%)	74 441 (3.2%)	79 703 (3.4%)	84 552 (3.6%)	88 781 (3.7%)	92 548 (3.9%)	95 602 (4.0%)	98 548 (4.1%)	-	3.06	3.04- 3.08
Diabetes	14 330 (0.5%)	14 707 (0.5%)	14 935 (0.5%)	15 105 (0.5%)	15 251 (0.5%)	15 148 (0.5%)	15 261 (0.5%)	15 692 (0.5%)	16 150 (0.5%)	-	1.77	1.75- 1.79
Deaths	675	685	584	564	590	538	605	560	571	507	-	-
SCD	47	48	44	43	43	39	34	42	40	45	-	-

567 Suppl. Table 3: Characteristics of out-of-hospital cardiac arrest victims, stratified by sex and time group

		Overall	2001-2003	2004-2007	2008-2011	2012-2015	2016-2019	Est. 19-year relative risk	95%CI RR
Female	Number	757	86	142	151	151	227		
	Age	24 (17-31)	25 (19-32)	25 (16-32)	26 (20-32)	23 (16-30)	24 (17-30)	-0.75 yr	-3.22 – 1.72
	Public location	190 (33%)	4 (44%)	16 (29%)	42 (32%)	49 (33%)	79 (35%)	1.10	0.66 – 1.91
	Shock. rhythm	125 (18%)	15 (19%)	14 (11%)	25 (18%)	26 (18%)	45 (21%)	1.57	0.90 – 2.78
	Bystander witnessed	264 (35%)	22 (26%)	46 (32%)	48 (32%)	60 (40%)	88 (39%)	1.49	1.07 – 2.10
	Bystander CPR	453 (60%)	23 (27%)	52 (37%)	80 (53%)	111 (74%)	187 (82%)		
	Bystander AED	26 (3.4%)	<=3	<= 3	<= 3	3 (2.0%)	20 (8.9%)	41.2	7.19 – 334.00
	30-day survival	164 (22%)	3 (3.5%)	18 (13%)	28 (19%)	43 (28%)	72 (33%)	6.07	3.61 – 10.40
Male	Number	1 805	246	330	376	324	529		
	Age	26 (19-31)	27 (21-32)	27 (19-32)	25 (19-31)	25 (19-31)	24 (19-31)	-1.56yr	-3.02 to -0.10
	Public location	592 (44%)	11 (65%)	62 (47%)	153 (45%)	131 (41%)	235 (45%)	0.91	0.70 – 1.20
	Shock. rhythm	314 (19%)	50 (22%)	48 (16%)	63 (19%)	59 (19%)	94 (19%)	1.02	0.73 – 1.43
	Bystander witnessed	621 (35%)	71 (29%)	99 (30%)	128 (34%)	117 (36%)	206 (39%)	1.46	1.17 – 1.81
	Bystander CPR	1 016 (56%)	75 (30%)	120 (36%)	198 (53%)	213 (66%)	410 (78%)		
	Bystander AED	56 (3.1%)	<= 5	<= 5	5 (1.3%)	8 (2.5%)	37 (7.2%)	15.00	5.26 – 47.3
	30-day survival	282 (16%)	10 (4.1%)	31 (9.4%)	44 (12%)	61 (19%)	136 (26%)	6.11	4.09 – 19.25

¹Median (IQR); n (%)

AED: automated external defibrillators, CPR: cardiopulmonary resuscitation